Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review
Biosci Trends. 2024 Apr 24. doi: 10.5582/bst.2024.01062. Online ahead of print.ABSTRACTAntiretroviral therapy (ART) has significantly enhanced the outlook for people with HIV(PWH), yet certain ART medications can adversely affect the renal function of these patients. Of particular concern is the nephrotoxicity associated with tenofovir disoproxil fumarate (TDF). Compared to TDF, tenofovir alafenamide (TAF), another prodrug of tenofovir (TFV), results in lower TFV plasma levels, thereby alleviating the TFV-associated mitochondrial toxicity on proximal renal tubular cells. Currently, numerous clinical trials and real-world s...
Source: BioScience Trends - April 24, 2024 Category: Biomedical Science Authors: Fang Zhao Hongzhou Lu Source Type: research
Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial
ConclusionPotential neural mechanisms underlying cognitive improvement after discontinuing EFV in PLWH were found in subcortical functioning, with our findings suggesting that EFV ’s effect on attention and processing speed is, at least partially, mediated by reactive inhibition.Trial RegistrationClinicaltrials.gov identifier [NCT02308332]. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 20, 2024 Category: Infectious Diseases Source Type: research
Characterization of mutations in hepatitis B virus DNA isolated from Japanese HBsAg-positive blood donors in 2021 and 2022
In this study, we isolated hepatitis B virus (HBV) DNA from 58 of 169 hepatitis B surface antigen (HBsAg)-positive blood samples from Japanese blood donors and determined the nucleotide sequence encoding the small envelope protein. DNA from six (10%) of the samples had VEMs, but no missense mutations, such as G145R, were detected. Complete HBV genome sequences were obtained from 29 of the 58 samples; the viral genotype was A1 in one (3%), A2 in three (10%), B1 in nine (31%), B2 in five (17%), B4 in one (3%), and C2 in 10 (34%) samples. Tenofovir-resistance mutations were detected in two (7%) samples. In addition, several c...
Source: Archives of Virology - April 18, 2024 Category: Virology Source Type: research
Research news in clinical context
Published in STI: Self-start HIV postexposure prophylaxis after sexual exposure to reduce time to first dose The efficacy of HIV post-exposure prophylaxis (PEP) increases with a shorter time to treatment initiation. This randomised, prospective, open-label study among men who have sex with men (MSM) in the UK assigned 139 participants to either a 5-day PEP starter pack of emtricitabine/tenofovir disoproxil fumarate/maraviroc, or to the standard of care (SOC) PEP access through sexual health clinics or accident and emergency units. There was a significant reduction in time from sex to first PEP dose in the starter pack arm ...
Source: Sexually Transmitted Infections - April 18, 2024 Category: Sexual Medicine Authors: Tan, R. K. J., Herbert, R., Vielot, N. A. Tags: Perspective Source Type: research
Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective - prospective multicenter study
Preventing disease progression and viral suppression are the main goals of antiviral therapy in chronic hepatitis B (CHB). Liver stiffness measurement (LSM) by transient elastography is a reliable non-invasive... (Source: BMC Gastroenterology)
Source: BMC Gastroenterology - April 12, 2024 Category: Gastroenterology Authors: Hariklia Kranidioti, Konstantinos Zisimopoulos, Theodora Oikonomou, Theodoros Voulgaris, Spyros Siakavellas, Polixeni Agorastou, Melanie Deutsch, Christos Triantos, Ioannis Goulis, George Papatheodoridis and Spilios Manolakopoulos Tags: Research Source Type: research
Reply to "Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in HBV patients"
Clin Mol Hepatol. 2024 Apr 11. doi: 10.3350/cmh.2024.0228. Online ahead of print.NO ABSTRACTPMID:38600870 | DOI:10.3350/cmh.2024.0228 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 11, 2024 Category: Gastroenterology Authors: Pin-Nan Cheng Ming-Lung Yu Source Type: research
Clinical benefits of novel non ‐nucleoside reverse transcriptase inhibitors: A prospective cohort study
ConclusionsBoth regimens showed good virological effectiveness; however, compared with ANV+3TC+TDF, the EFV+3TC+TDF regimen reduced the prevalence of HIV-related symptoms. (Source: Immunity, Inflammation and Disease)
Source: Immunity, Inflammation and Disease - April 5, 2024 Category: Allergy & Immunology Authors: Shujing Ma,
Xiaoxin Xie,
Yanhua Fu,
Lin Gan,
Xiaoyan Yang,
Linghong Kong,
Jun Li,
Hai Long Tags: ORIGINAL ARTICLE Source Type: research
Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers
ConclusionsAlthough TAF AUC andCmax 90% CIs fell outside the pre-defined criteria (0.62 –1.11 and 0.65–1.01, respectively), no consistent effect on TAF PK was observed, likely due to high inter-subject variability. Moreover, there are several reasons to rely on TFV exposure as being more clinically relevant than TAF exposure. Therefore, we found no clinically relevant interactions in this study. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - April 4, 2024 Category: Drugs & Pharmacology Source Type: research
Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
No study has comparing hepatitis B virus (HBV) relapse rates among patients with both cancer and hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) who completed anti-viral prophylaxis for chemot... (Source: Virology Journal)
Source: Virology Journal - April 3, 2024 Category: Virology Authors: Hsin-Wei Fang, Po-Lin Tseng, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu and Chien-Hung Chen Tags: Research Source Type: research
Comparison of the Effects of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Liver Function in Patients with Hepatitis B: A Meta-analysis
CONCLUSIONS: Both TAF and TDF are effective in the treatment of CHB, but the former is preferred due to its higher safety profile.PMID:38551440 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Longda Chen Qingqing Jiang Xun Chen Source Type: research
Comparison of the Effects of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Liver Function in Patients with Hepatitis B: A Meta-analysis
CONCLUSIONS: Both TAF and TDF are effective in the treatment of CHB, but the former is preferred due to its higher safety profile.PMID:38551440 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Longda Chen Qingqing Jiang Xun Chen Source Type: research
Comparison of the Effects of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Liver Function in Patients with Hepatitis B: A Meta-analysis
CONCLUSIONS: Both TAF and TDF are effective in the treatment of CHB, but the former is preferred due to its higher safety profile.PMID:38551440 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Longda Chen Qingqing Jiang Xun Chen Source Type: research
